Hims & Hers rises as Lilly expands weight-loss drug access through platform
** Shares of telehealth platform Hims & Hers Health HIMS.N rise 7.6% to $25.88 premarket
** Cos say Eli Lilly's LLY.N obesity drugs Zepbound and Foundayo will be available through the Hims & Hers platform under a new agreement
** Eligible patients prescribed the treatments by providers on its platform can access Lilly's self-pay prices without leaving the Hims & Hers platform
** Lilly's obesity injection Zepbound will be available starting at $299 per month, while oral obesity drug Foundayo will start at $149 per month
** Cos say patients can complete consultations, receive prescriptions if appropriate and have FDA-approved Lilly medicines shipped directly to their homes
** HIMS says it has never offered compounded copies of Lilly's GLP-1 obesity medicines and has committed not to do so in the future
** As of last close, stock down ~26% YTD